-
1
-
-
70349243437
-
Emerging therapies for chronic kidney disease: what is their role?
-
Vilayur E., Harris D.C. Emerging therapies for chronic kidney disease: what is their role?. Nat Rev Nephrol 2009, 5:375-383.
-
(2009)
Nat Rev Nephrol
, vol.5
, pp. 375-383
-
-
Vilayur, E.1
Harris, D.C.2
-
2
-
-
77949541746
-
Proteinuria: an enzymatic disease of the podocyte?
-
Mundel P., Reiser J. Proteinuria: an enzymatic disease of the podocyte?. Kidney Int 2010, 77:571-580.
-
(2010)
Kidney Int
, vol.77
, pp. 571-580
-
-
Mundel, P.1
Reiser, J.2
-
3
-
-
70249101386
-
Therapeutic targets in the podocyte: findings in anti-slit diaphragm antibody-induced nephropathy
-
Kawachi H., Han G.D., Miyauchi N., Hashimoto T., Suzuki K., Shimizu F. Therapeutic targets in the podocyte: findings in anti-slit diaphragm antibody-induced nephropathy. J Nephrol 2009, 22:450-456.
-
(2009)
J Nephrol
, vol.22
, pp. 450-456
-
-
Kawachi, H.1
Han, G.D.2
Miyauchi, N.3
Hashimoto, T.4
Suzuki, K.5
Shimizu, F.6
-
4
-
-
77951258596
-
Enzymatic disease of the podocyte
-
Kistler A.D., Peev V., Forst A.L., El Hindi S., Altintas M.M., Reiser J. Enzymatic disease of the podocyte. Pediatr Nephrol 2010, 25:1017-1023.
-
(2010)
Pediatr Nephrol
, vol.25
, pp. 1017-1023
-
-
Kistler, A.D.1
Peev, V.2
Forst, A.L.3
El Hindi, S.4
Altintas, M.M.5
Reiser, J.6
-
5
-
-
77950517549
-
Toward the development of podocyte-specific drugs
-
Reiser J., Gupta V., Kistler A.D. Toward the development of podocyte-specific drugs. Kidney Int 2010, 77:662-668.
-
(2010)
Kidney Int
, vol.77
, pp. 662-668
-
-
Reiser, J.1
Gupta, V.2
Kistler, A.D.3
-
6
-
-
78650643239
-
The podocyte as a direct target of immunosuppressive agents
-
Schonenberger E., Ehrich J.H., Haller H., Schiffer M. The podocyte as a direct target of immunosuppressive agents. Nephrol Dial Transplant 2011, 26:18-24.
-
(2011)
Nephrol Dial Transplant
, vol.26
, pp. 18-24
-
-
Schonenberger, E.1
Ehrich, J.H.2
Haller, H.3
Schiffer, M.4
-
7
-
-
33748430642
-
Direct effects of dexamethasone on human podocytes
-
Xing C.Y., Saleem M.A., Coward R.J., Ni L., Witherden I.R., Mathieson P.W. Direct effects of dexamethasone on human podocytes. Kidney Int 2006, 70:1038-1045.
-
(2006)
Kidney Int
, vol.70
, pp. 1038-1045
-
-
Xing, C.Y.1
Saleem, M.A.2
Coward, R.J.3
Ni, L.4
Witherden, I.R.5
Mathieson, P.W.6
-
8
-
-
67649134882
-
Reduction in VEGF protein and phosphorylated nephrin associated with proteinuria in adriamycin nephropathy rats
-
Fan Q., Xing Y., Ding J., Guan N. Reduction in VEGF protein and phosphorylated nephrin associated with proteinuria in adriamycin nephropathy rats. Nephron Exp Nephrol 2009, 111:e92-e102.
-
(2009)
Nephron Exp Nephrol
, vol.111
-
-
Fan, Q.1
Xing, Y.2
Ding, J.3
Guan, N.4
-
9
-
-
33646133214
-
The effect of dexamethasone on defective nephrin transport caused by ER stress: a potential mechanism for the therapeutic action of glucocorticoids in the acquired glomerular diseases
-
Fujii Y., Khoshnoodi J., Takenaka H., et al. The effect of dexamethasone on defective nephrin transport caused by ER stress: a potential mechanism for the therapeutic action of glucocorticoids in the acquired glomerular diseases. Kidney Int 2006, 69:1350-1359.
-
(2006)
Kidney Int
, vol.69
, pp. 1350-1359
-
-
Fujii, Y.1
Khoshnoodi, J.2
Takenaka, H.3
-
10
-
-
16244409244
-
Differential proteomic analysis of proteins induced by glucocorticoids in cultured murine podocytes
-
Ransom R.F., Vega-Warner V., Smoyer W.E., Klein J. Differential proteomic analysis of proteins induced by glucocorticoids in cultured murine podocytes. Kidney Int 2005, 67:1275-1285.
-
(2005)
Kidney Int
, vol.67
, pp. 1275-1285
-
-
Ransom, R.F.1
Vega-Warner, V.2
Smoyer, W.E.3
Klein, J.4
-
11
-
-
2442505604
-
ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses
-
Berg A.L., Arnadottir M. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrol Dial Transplant 2004, 19:1305-1307.
-
(2004)
Nephrol Dial Transplant
, vol.19
, pp. 1305-1307
-
-
Berg, A.L.1
Arnadottir, M.2
-
12
-
-
31044441980
-
A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy
-
Ponticelli C., Passerini P., Salvadori M., et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 2006, 47:233-240.
-
(2006)
Am J Kidney Dis
, vol.47
, pp. 233-240
-
-
Ponticelli, C.1
Passerini, P.2
Salvadori, M.3
-
13
-
-
77955609123
-
Melanocortin 1 receptor agonists reduce proteinuria
-
Lindskog A., Ebefors K., Johansson M.E., et al. Melanocortin 1 receptor agonists reduce proteinuria. J Am Soc Nephrol 2010, 21:1290-1298.
-
(2010)
J Am Soc Nephrol
, vol.21
, pp. 1290-1298
-
-
Lindskog, A.1
Ebefors, K.2
Johansson, M.E.3
-
14
-
-
51349162919
-
The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A
-
Faul C., Donnelly M., Merscher-Gomez S., et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008, 14:931-938.
-
(2008)
Nat Med
, vol.14
, pp. 931-938
-
-
Faul, C.1
Donnelly, M.2
Merscher-Gomez, S.3
-
15
-
-
77954534869
-
Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies
-
Bensman A., Niaudet P. Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies. Pediatr Nephrol 2010, 25:1197-1199.
-
(2010)
Pediatr Nephrol
, vol.25
, pp. 1197-1199
-
-
Bensman, A.1
Niaudet, P.2
-
16
-
-
34250175849
-
Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats
-
Zhang Y., Chen B., Hou X.H., et al. Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats. Chin Med J (Engl) 2007, 120:988-995.
-
(2007)
Chin Med J (Engl)
, vol.120
, pp. 988-995
-
-
Zhang, Y.1
Chen, B.2
Hou, X.H.3
-
17
-
-
32644457806
-
Mycophenolate mofetil ameliorates nephropathy in the obese Zucker rat
-
Rodriguez-Iturbe B., Quiroz Y., Shahkarami A., Li Z., Vaziri N.D. Mycophenolate mofetil ameliorates nephropathy in the obese Zucker rat. Kidney Int 2005, 68:1041-1047.
-
(2005)
Kidney Int
, vol.68
, pp. 1041-1047
-
-
Rodriguez-Iturbe, B.1
Quiroz, Y.2
Shahkarami, A.3
Li, Z.4
Vaziri, N.D.5
-
18
-
-
77951490147
-
The accumulated experience with the use of mycophenolate mofetil in primary glomerulonephritis
-
Koukoulaki M., Goumenos D.S. The accumulated experience with the use of mycophenolate mofetil in primary glomerulonephritis. Expert Opin Investig Drugs 2010, 19:673-687.
-
(2010)
Expert Opin Investig Drugs
, vol.19
, pp. 673-687
-
-
Koukoulaki, M.1
Goumenos, D.S.2
-
19
-
-
68549117277
-
Monoclonal antibodies for podocytopathies: rationale and clinical responses
-
Marasa M., Kopp J.B. Monoclonal antibodies for podocytopathies: rationale and clinical responses. Nat Rev Nephrol 2009, 5:337-348.
-
(2009)
Nat Rev Nephrol
, vol.5
, pp. 337-348
-
-
Marasa, M.1
Kopp, J.B.2
-
20
-
-
77950362581
-
Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine
-
Fujinaga S., Hirano D., Nishizaki N., et al. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol 2010, 25:539-544.
-
(2010)
Pediatr Nephrol
, vol.25
, pp. 539-544
-
-
Fujinaga, S.1
Hirano, D.2
Nishizaki, N.3
-
21
-
-
79960553247
-
-
Effect of rituximab on the regulation of sphingomyelinase-like phosphodiesterase 3b-precursor in recurrent FSGS. Poster presented at: American Society of Nephrology Annual Meeting; Denver, CO
-
Fornoni A, Sagheshima J. Effect of rituximab on the regulation of sphingomyelinase-like phosphodiesterase 3b-precursor in recurrent FSGS. Poster presented at: American Society of Nephrology Annual Meeting; 2010; Denver, CO.
-
(2010)
-
-
Fornoni, A.1
Sagheshima, J.2
-
22
-
-
60549091725
-
Omega-3 fatty acid rich diet prevents diabetic renal disease
-
Garman J.H., Mulroney S., Manigrasso M., Flynn E., Maric C. Omega-3 fatty acid rich diet prevents diabetic renal disease. Am J Physiol Renal Physiol 2009, 296:F306-F316.
-
(2009)
Am J Physiol Renal Physiol
, vol.296
-
-
Garman, J.H.1
Mulroney, S.2
Manigrasso, M.3
Flynn, E.4
Maric, C.5
-
23
-
-
0033917537
-
Suppressive effects of fish oil on mesangial cell proliferation in vitro and in vivo
-
Grande J.P., Walker H.J., Holub B.J., et al. Suppressive effects of fish oil on mesangial cell proliferation in vitro and in vivo. Kidney Int 2000, 57:1027-1040.
-
(2000)
Kidney Int
, vol.57
, pp. 1027-1040
-
-
Grande, J.P.1
Walker, H.J.2
Holub, B.J.3
-
24
-
-
66849102001
-
The effect of n-3 long-chain polyunsaturated fatty acid supplementation on urine protein excretion and kidney function: meta-analysis of clinical trials
-
Miller E.R., Juraschek S.P., Appel L.J., et al. The effect of n-3 long-chain polyunsaturated fatty acid supplementation on urine protein excretion and kidney function: meta-analysis of clinical trials. Am J Clin Nutr 2009, 89:1937-1945.
-
(2009)
Am J Clin Nutr
, vol.89
, pp. 1937-1945
-
-
Miller, E.R.1
Juraschek, S.P.2
Appel, L.J.3
-
25
-
-
77952689528
-
Suppression of nephrin expression by TNF-alpha via interfering with the cAMP-retinoic acid receptor pathway
-
Saito Y., Okamura M., Nakajima S., et al. Suppression of nephrin expression by TNF-alpha via interfering with the cAMP-retinoic acid receptor pathway. Am J Physiol Renal Physiol 2010, 298:F1436-F1444.
-
(2010)
Am J Physiol Renal Physiol
, vol.298
-
-
Saito, Y.1
Okamura, M.2
Nakajima, S.3
-
26
-
-
0032782860
-
TNF-alpha induces actin cytoskeleton reorganization in glomerular epithelial cells involving tyrosine phosphorylation of paxillin and focal adhesion kinase
-
Koukouritaki S.B., Vardaki E.A., Papakonstanti E.A., Lianos E., Stournaras C., Emmanouel D.S. TNF-alpha induces actin cytoskeleton reorganization in glomerular epithelial cells involving tyrosine phosphorylation of paxillin and focal adhesion kinase. Mol Med 1999, 5:382-392.
-
(1999)
Mol Med
, vol.5
, pp. 382-392
-
-
Koukouritaki, S.B.1
Vardaki, E.A.2
Papakonstanti, E.A.3
Lianos, E.4
Stournaras, C.5
Emmanouel, D.S.6
-
27
-
-
67651085542
-
Inhibition of tumour necrosis factor alpha in idiopathic membranous nephropathy: a pilot study
-
Lionaki S., Siamopoulos K., Theodorou I., et al. Inhibition of tumour necrosis factor alpha in idiopathic membranous nephropathy: a pilot study. Nephrol Dial Transplant 2009, 24:2144-2150.
-
(2009)
Nephrol Dial Transplant
, vol.24
, pp. 2144-2150
-
-
Lionaki, S.1
Siamopoulos, K.2
Theodorou, I.3
-
28
-
-
71849107687
-
Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group
-
Joy M.S., Gipson D.S., Powell L., et al. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis 2010, 55:50-60.
-
(2010)
Am J Kidney Dis
, vol.55
, pp. 50-60
-
-
Joy, M.S.1
Gipson, D.S.2
Powell, L.3
-
30
-
-
77950208651
-
Effects of TGF-beta on podocyte growth and disease progression in proliferative podocytopathies
-
Lee H.S., Song C.Y. Effects of TGF-beta on podocyte growth and disease progression in proliferative podocytopathies. Kidney Blood Press Res 2010, 33:24-29.
-
(2010)
Kidney Blood Press Res
, vol.33
, pp. 24-29
-
-
Lee, H.S.1
Song, C.Y.2
-
31
-
-
31644431555
-
The cyclin-dependent kinase inhibitor p21 is required for TGF-beta1-induced podocyte apoptosis
-
Wada T., Pippin J.W., Terada Y., Shankland S.J. The cyclin-dependent kinase inhibitor p21 is required for TGF-beta1-induced podocyte apoptosis. Kidney Int 2005, 68:1618-1629.
-
(2005)
Kidney Int
, vol.68
, pp. 1618-1629
-
-
Wada, T.1
Pippin, J.W.2
Terada, Y.3
Shankland, S.J.4
-
32
-
-
0034836835
-
Apoptosis in podocytes induced by TGF-beta and Smad7
-
Schiffer M., Bitzer M., Roberts I.S., et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001, 108:807-816.
-
(2001)
J Clin Invest
, vol.108
, pp. 807-816
-
-
Schiffer, M.1
Bitzer, M.2
Roberts, I.S.3
-
33
-
-
0038205926
-
Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat
-
Benigni A., Zoja C., Corna D., et al. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003, 14:1816-1824.
-
(2003)
J Am Soc Nephrol
, vol.14
, pp. 1816-1824
-
-
Benigni, A.1
Zoja, C.2
Corna, D.3
-
34
-
-
36048950801
-
Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria
-
Wang A., Ziyadeh F.N., Lee E.Y., et al. Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. Am J Physiol Renal Physiol 2007, 293:F1657-F1665.
-
(2007)
Am J Physiol Renal Physiol
, vol.293
-
-
Wang, A.1
Ziyadeh, F.N.2
Lee, E.Y.3
-
35
-
-
24944563923
-
ATRA induces podocyte differentiation and alters nephrin and podocin expression in vitro and in vivo
-
Vaughan M.R., Pippin J.W., Griffin S.V., et al. ATRA induces podocyte differentiation and alters nephrin and podocin expression in vitro and in vivo. Kidney Int 2005, 68:133-144.
-
(2005)
Kidney Int
, vol.68
, pp. 133-144
-
-
Vaughan, M.R.1
Pippin, J.W.2
Griffin, S.V.3
-
36
-
-
73449096477
-
PTH-induced internalization of apical membrane NaPi2a: role of actin and myosin VI
-
Blaine J., Okamura K., Giral H., et al. PTH-induced internalization of apical membrane NaPi2a: role of actin and myosin VI. Am J Physiol Cell Physiol 2009, 297:C1339-C1346.
-
(2009)
Am J Physiol Cell Physiol
, vol.297
-
-
Blaine, J.1
Okamura, K.2
Giral, H.3
-
37
-
-
33845973761
-
Retinoic acid inhibits HIV-1-induced podocyte proliferation through the cAMP pathway
-
He J.C., Lu T.C., Fleet M., et al. Retinoic acid inhibits HIV-1-induced podocyte proliferation through the cAMP pathway. J Am Soc Nephrol 2007, 18:93-102.
-
(2007)
J Am Soc Nephrol
, vol.18
, pp. 93-102
-
-
He, J.C.1
Lu, T.C.2
Fleet, M.3
-
38
-
-
0037378798
-
Retinoids regulate the repairing process of the podocytes in puromycin aminonucleoside-induced nephrotic rats
-
Suzuki A., Ito T., Imai E., et al. Retinoids regulate the repairing process of the podocytes in puromycin aminonucleoside-induced nephrotic rats. J Am Soc Nephrol 2003, 14:981-991.
-
(2003)
J Am Soc Nephrol
, vol.14
, pp. 981-991
-
-
Suzuki, A.1
Ito, T.2
Imai, E.3
-
39
-
-
9444258635
-
Effect of retinoic acid in experimental diabetic nephropathy
-
Han S.Y., So G.A., Jee Y.H., et al. Effect of retinoic acid in experimental diabetic nephropathy. Immunol Cell Biol 2004, 82:568-576.
-
(2004)
Immunol Cell Biol
, vol.82
, pp. 568-576
-
-
Han, S.Y.1
So, G.A.2
Jee, Y.H.3
-
40
-
-
33846686500
-
Therapeutic effect of all-trans-retinoic acid (at-RA) on an autoimmune nephritis experimental model: role of the VLA-4 integrin
-
Escribese M.M., Conde E., Martin A., et al. Therapeutic effect of all-trans-retinoic acid (at-RA) on an autoimmune nephritis experimental model: role of the VLA-4 integrin. BMC Nephrol 2007, 8:3.
-
(2007)
BMC Nephrol
, vol.8
, pp. 3
-
-
Escribese, M.M.1
Conde, E.2
Martin, A.3
-
41
-
-
49749144405
-
Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease
-
Fried L.F. Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease. Kidney Int 2008, 74:571-576.
-
(2008)
Kidney Int
, vol.74
, pp. 571-576
-
-
Fried, L.F.1
-
42
-
-
58449110318
-
Rosuvastatin protects against podocyte apoptosis in vitro
-
Cormack-Aboud F.C., Brinkkoetter P.T., Pippin J.W., Shankland S.J., Durvasula R.V. Rosuvastatin protects against podocyte apoptosis in vitro. Nephrol Dial Transplant 2009, 24:404-412.
-
(2009)
Nephrol Dial Transplant
, vol.24
, pp. 404-412
-
-
Cormack-Aboud, F.C.1
Brinkkoetter, P.T.2
Pippin, J.W.3
Shankland, S.J.4
Durvasula, R.V.5
-
43
-
-
34547743999
-
Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice
-
Fujii M., Inoguchi T., Maeda Y., et al. Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice. Kidney Int 2007, 72:473-480.
-
(2007)
Kidney Int
, vol.72
, pp. 473-480
-
-
Fujii, M.1
Inoguchi, T.2
Maeda, Y.3
-
44
-
-
33645455275
-
Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling
-
Shibata S., Nagase M., Fujita T. Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J Am Soc Nephrol 2006, 17:754-764.
-
(2006)
J Am Soc Nephrol
, vol.17
, pp. 754-764
-
-
Shibata, S.1
Nagase, M.2
Fujita, T.3
-
45
-
-
33746673912
-
Meta-analysis: the effect of statins on albuminuria
-
Douglas K., O'Malley P.G., Jackson J.L. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006, 145:117-124.
-
(2006)
Ann Intern Med
, vol.145
, pp. 117-124
-
-
Douglas, K.1
O'Malley, P.G.2
Jackson, J.L.3
-
46
-
-
78249284594
-
T-type Ca channel blockade as a determinant of kidney protection
-
Hayashi K., Homma K., Wakino S., et al. T-type Ca channel blockade as a determinant of kidney protection. Keio J Med 2010, 59:84-95.
-
(2010)
Keio J Med
, vol.59
, pp. 84-95
-
-
Hayashi, K.1
Homma, K.2
Wakino, S.3
-
47
-
-
73249126058
-
Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy
-
Sasaki H., Saiki A., Endo K., et al. Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy. J Atheroscler Thromb 2009, 16:568-575.
-
(2009)
J Atheroscler Thromb
, vol.16
, pp. 568-575
-
-
Sasaki, H.1
Saiki, A.2
Endo, K.3
-
48
-
-
77956403931
-
Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats
-
Takai S., Jin D., Sakonjo H., Miyazaki M. Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats. Hypertens Res 2010, 33:953-959.
-
(2010)
Hypertens Res
, vol.33
, pp. 953-959
-
-
Takai, S.1
Jin, D.2
Sakonjo, H.3
Miyazaki, M.4
-
49
-
-
58949095363
-
Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy
-
Toto R.D., Tian M., Fakouhi K., Champion A., Bacher P. Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy. J Clin Hypertens (Greenwich) 2008, 10:761-769.
-
(2008)
J Clin Hypertens (Greenwich)
, vol.10
, pp. 761-769
-
-
Toto, R.D.1
Tian, M.2
Fakouhi, K.3
Champion, A.4
Bacher, P.5
-
50
-
-
34548028268
-
Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis
-
Ishimitsu T., Kameda T., Akashiba A., et al. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 2007, 30:621-626.
-
(2007)
Hypertens Res
, vol.30
, pp. 621-626
-
-
Ishimitsu, T.1
Kameda, T.2
Akashiba, A.3
-
51
-
-
36249006990
-
Rosiglitazone decreases albuminuria in type 2 diabetic patients
-
Miyazaki Y., Cersosimo E., Triplitt C., DeFronzo R.A. Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int 2007, 72:1367-1373.
-
(2007)
Kidney Int
, vol.72
, pp. 1367-1373
-
-
Miyazaki, Y.1
Cersosimo, E.2
Triplitt, C.3
DeFronzo, R.A.4
-
52
-
-
33646939809
-
Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone
-
Benigni A., Zoja C., Tomasoni S., et al. Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. J Am Soc Nephrol 2006, 17:1624-1632.
-
(2006)
J Am Soc Nephrol
, vol.17
, pp. 1624-1632
-
-
Benigni, A.1
Zoja, C.2
Tomasoni, S.3
-
53
-
-
0036116895
-
Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat
-
Yamashita H., Nagai Y., Takamura T., Nohara E., Kobayashi K. Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat. Metabolism 2002, 51:403-408.
-
(2002)
Metabolism
, vol.51
, pp. 403-408
-
-
Yamashita, H.1
Nagai, Y.2
Takamura, T.3
Nohara, E.4
Kobayashi, K.5
-
54
-
-
36649011357
-
Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model
-
Ohtomo S., Izuhara Y., Takizawa S., et al. Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model. Kidney Int 2007, 72:1512-1519.
-
(2007)
Kidney Int
, vol.72
, pp. 1512-1519
-
-
Ohtomo, S.1
Izuhara, Y.2
Takizawa, S.3
-
55
-
-
77951621387
-
Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis
-
Sarafidis P.A., Stafylas P.C., Georgianos P.I., Saratzis A.N., Lasaridis A.N. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis 2010, 55:835-847.
-
(2010)
Am J Kidney Dis
, vol.55
, pp. 835-847
-
-
Sarafidis, P.A.1
Stafylas, P.C.2
Georgianos, P.I.3
Saratzis, A.N.4
Lasaridis, A.N.5
-
56
-
-
0036073755
-
1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system
-
Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002, 110:229-238.
-
(2002)
J Clin Invest
, vol.110
, pp. 229-238
-
-
Li, Y.C.1
Kong, J.2
Wei, M.3
Chen, Z.F.4
Liu, S.Q.5
Cao, L.P.6
-
57
-
-
67651115709
-
Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats
-
Matsui I., Hamano T., Tomida K., et al. Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats. Nephrol Dial Transplant 2009, 24:2354-2361.
-
(2009)
Nephrol Dial Transplant
, vol.24
, pp. 2354-2361
-
-
Matsui, I.1
Hamano, T.2
Tomida, K.3
-
58
-
-
56549101354
-
Suppression of renin-angiotensin gene expression in the kidney by paricalcitol
-
Freundlich M., Quiroz Y., Zhang Z., et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008, 74:1394-1402.
-
(2008)
Kidney Int
, vol.74
, pp. 1394-1402
-
-
Freundlich, M.1
Quiroz, Y.2
Zhang, Z.3
-
59
-
-
78651384347
-
Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury
-
He W., Kang Y.S., Dai C., Liu Y. Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol 2011, 22:90-103.
-
(2011)
J Am Soc Nephrol
, vol.22
, pp. 90-103
-
-
He, W.1
Kang, Y.S.2
Dai, C.3
Liu, Y.4
-
60
-
-
59449105533
-
1,25-Dihydroxyvitamin D(3) prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway
-
Xiao H., Shi W., Liu S., et al. 1,25-Dihydroxyvitamin D(3) prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway. Am J Nephrol 2009, 30:34-43.
-
(2009)
Am J Nephrol
, vol.30
, pp. 34-43
-
-
Xiao, H.1
Shi, W.2
Liu, S.3
-
61
-
-
78149359262
-
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial
-
de Zeeuw D., Agarwal R., Amdahl M., et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010, 376:1543-1551.
-
(2010)
Lancet
, vol.376
, pp. 1543-1551
-
-
de Zeeuw, D.1
Agarwal, R.2
Amdahl, M.3
-
62
-
-
47949128459
-
The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis
-
McCormick B.B., Sydor A., Akbari A., Fergusson D., Doucette S., Knoll G. The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis 2008, 52:454-463.
-
(2008)
Am J Kidney Dis
, vol.52
, pp. 454-463
-
-
McCormick, B.B.1
Sydor, A.2
Akbari, A.3
Fergusson, D.4
Doucette, S.5
Knoll, G.6
-
63
-
-
0035954017
-
Use of pentoxifylline in membranous nephropathy
-
Ducloux D., Bresson-Vautrin C., Chalopin J. Use of pentoxifylline in membranous nephropathy. Lancet 2001, 357:1672-1673.
-
(2001)
Lancet
, vol.357
, pp. 1672-1673
-
-
Ducloux, D.1
Bresson-Vautrin, C.2
Chalopin, J.3
-
64
-
-
49949102418
-
Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial
-
Lin S.L., Chen Y.M., Chiang W.C., Wu K.D., Tsai T.J. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. Am J Kidney Dis 2008, 52:464-474.
-
(2008)
Am J Kidney Dis
, vol.52
, pp. 464-474
-
-
Lin, S.L.1
Chen, Y.M.2
Chiang, W.C.3
Wu, K.D.4
Tsai, T.J.5
-
65
-
-
13444271063
-
Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats
-
Leh S., Vaagnes O., Margolin S.B., Iversen B.M., Forslund T. Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats. Nephrol Dial Transplant 2005, 20:71-82.
-
(2005)
Nephrol Dial Transplant
, vol.20
, pp. 71-82
-
-
Leh, S.1
Vaagnes, O.2
Margolin, S.B.3
Iversen, B.M.4
Forslund, T.5
-
66
-
-
74149086684
-
Renoprotective properties of pirfenidone in subtotally nephrectomized rats
-
Takakuta K., Fujimori A., Chikanishi T., et al. Renoprotective properties of pirfenidone in subtotally nephrectomized rats. Eur J Pharmacol 2010, 629:118-124.
-
(2010)
Eur J Pharmacol
, vol.629
, pp. 118-124
-
-
Takakuta, K.1
Fujimori, A.2
Chikanishi, T.3
-
67
-
-
68149178848
-
Pirfenidone is renoprotective in diabetic kidney disease
-
RamachandraRao S.P., Zhu Y., Ravasi T., et al. Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol 2009, 20:1765-1775.
-
(2009)
J Am Soc Nephrol
, vol.20
, pp. 1765-1775
-
-
RamachandraRao, S.P.1
Zhu, Y.2
Ravasi, T.3
-
68
-
-
34548834734
-
Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis
-
Cho M.E., Smith D.C., Branton M.H., Penzak S.R., Kopp J.B. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007, 2:906-913.
-
(2007)
Clin J Am Soc Nephrol
, vol.2
, pp. 906-913
-
-
Cho, M.E.1
Smith, D.C.2
Branton, M.H.3
Penzak, S.R.4
Kopp, J.B.5
-
69
-
-
2542447966
-
Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy
-
Mifsud S., Kelly D.J., Qi W., et al. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. Nephron Physiol 2003, 95:83-91.
-
(2003)
Nephron Physiol
, vol.95
, pp. 83-91
-
-
Mifsud, S.1
Kelly, D.J.2
Qi, W.3
-
70
-
-
16644370226
-
Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model
-
Kelly D.J., Zhang Y., Gow R., Gilbert R.E. Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model. J Am Soc Nephrol 2004, 15:2619-2629.
-
(2004)
J Am Soc Nephrol
, vol.15
, pp. 2619-2629
-
-
Kelly, D.J.1
Zhang, Y.2
Gow, R.3
Gilbert, R.E.4
-
71
-
-
33745239220
-
Combination therapy with tranilast and angiotensin-converting enzyme inhibition provides additional renoprotection in the remnant kidney model
-
Kelly D.J., Zhang Y., Cox A.J., Gilbert R.E. Combination therapy with tranilast and angiotensin-converting enzyme inhibition provides additional renoprotection in the remnant kidney model. Kidney Int 2006, 69:1954-1960.
-
(2006)
Kidney Int
, vol.69
, pp. 1954-1960
-
-
Kelly, D.J.1
Zhang, Y.2
Cox, A.J.3
Gilbert, R.E.4
-
72
-
-
46349104473
-
Tranilast ameliorates experimental mesangial proliferative glomerulonephritis
-
Tokuyama H., Kelly D.J., Cox A., et al. Tranilast ameliorates experimental mesangial proliferative glomerulonephritis. Nephron Exp Nephrol 2008, 109:e1-e7.
-
(2008)
Nephron Exp Nephrol
, vol.109
-
-
Tokuyama, H.1
Kelly, D.J.2
Cox, A.3
-
73
-
-
0037015262
-
Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial
-
Holmes D.R., Savage M., LaBlanche J.M., et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2002, 106:1243-1250.
-
(2002)
Circulation
, vol.106
, pp. 1243-1250
-
-
Holmes, D.R.1
Savage, M.2
LaBlanche, J.M.3
-
74
-
-
0036362822
-
Tranilast slows the progression of advanced diabetic nephropathy
-
Soma J., Sugawara T., Huang Y.D., Nakajima J., Kawamura M. Tranilast slows the progression of advanced diabetic nephropathy. Nephron 2002, 92:693-698.
-
(2002)
Nephron
, vol.92
, pp. 693-698
-
-
Soma, J.1
Sugawara, T.2
Huang, Y.D.3
Nakajima, J.4
Kawamura, M.5
-
75
-
-
33749618332
-
Effect of tranilast in early-stage diabetic nephropathy
-
Soma J., Sato K., Saito H., Tsuchiya Y. Effect of tranilast in early-stage diabetic nephropathy. Nephrol Dial Transplant 2006, 21:2795-2799.
-
(2006)
Nephrol Dial Transplant
, vol.21
, pp. 2795-2799
-
-
Soma, J.1
Sato, K.2
Saito, H.3
Tsuchiya, Y.4
-
76
-
-
77955865476
-
Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro
-
Chen Z.H., Qin W.S., Zeng C.H., et al. Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro. Kidney Int 2010, 77:974-988.
-
(2010)
Kidney Int
, vol.77
, pp. 974-988
-
-
Chen, Z.H.1
Qin, W.S.2
Zeng, C.H.3
-
77
-
-
49749123825
-
Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro
-
Zheng C.X., Chen Z.H., Zeng C.H., Qin W.S., Li L.S., Liu Z.H. Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro. Kidney Int 2008, 74:596-612.
-
(2008)
Kidney Int
, vol.74
, pp. 596-612
-
-
Zheng, C.X.1
Chen, Z.H.2
Zeng, C.H.3
Qin, W.S.4
Li, L.S.5
Liu, Z.H.6
-
78
-
-
67049110419
-
Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours
-
Kitzen J.J., de Jonge M.J., Lamers C.H., et al. Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. Eur J Cancer 2009, 45:1764-1772.
-
(2009)
Eur J Cancer
, vol.45
, pp. 1764-1772
-
-
Kitzen, J.J.1
de Jonge, M.J.2
Lamers, C.H.3
-
79
-
-
0026758529
-
Effect of dipyridamole with or without aspirin on urine protein excretion in patients with membranous glomerulonephritis
-
De La Cruz J.P., Camara S., Frutos M.A., Sanchez De La Cuesta F. Effect of dipyridamole with or without aspirin on urine protein excretion in patients with membranous glomerulonephritis. Eur J Clin Pharmacol 1992, 43:307-309.
-
(1992)
Eur J Clin Pharmacol
, vol.43
, pp. 307-309
-
-
De La Cruz, J.P.1
Camara, S.2
Frutos, M.A.3
Sanchez De La Cuesta, F.4
-
80
-
-
0043032930
-
Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria
-
Kano K., Nishikura K., Yamada Y., Arisaka O. Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria. Clin Nephrol 2003, 60:85-89.
-
(2003)
Clin Nephrol
, vol.60
, pp. 85-89
-
-
Kano, K.1
Nishikura, K.2
Yamada, Y.3
Arisaka, O.4
-
81
-
-
33845743504
-
Meta-analysis of antiplatelet therapy for IgA nephropathy
-
Taji Y., Kuwahara T., Shikata S., Morimoto T. Meta-analysis of antiplatelet therapy for IgA nephropathy. Clin Exp Nephrol 2006, 10:268-273.
-
(2006)
Clin Exp Nephrol
, vol.10
, pp. 268-273
-
-
Taji, Y.1
Kuwahara, T.2
Shikata, S.3
Morimoto, T.4
-
82
-
-
33751404292
-
Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial
-
Yoshikawa N., Honda M., Iijima K., et al. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol 2006, 1:511-517.
-
(2006)
Clin J Am Soc Nephrol
, vol.1
, pp. 511-517
-
-
Yoshikawa, N.1
Honda, M.2
Iijima, K.3
-
83
-
-
0033855993
-
Effect of the antiplatelet drug dilazep dihydrochloride on urinary podocytes in patients in the early stage of diabetic nephropathy
-
Nakamura T., Ushiyama C., Shimada N., et al. Effect of the antiplatelet drug dilazep dihydrochloride on urinary podocytes in patients in the early stage of diabetic nephropathy. Diabetes Care 2000, 23:1168-1171.
-
(2000)
Diabetes Care
, vol.23
, pp. 1168-1171
-
-
Nakamura, T.1
Ushiyama, C.2
Shimada, N.3
-
84
-
-
78649926915
-
Darbepoetin-alpha treatment enhances glomerular regenerative process in the Thy-1 glomerulonephritis model
-
Canadillas S., Ortega R., Estepa J.C., et al. Darbepoetin-alpha treatment enhances glomerular regenerative process in the Thy-1 glomerulonephritis model. Am J Physiol Renal Physiol 2010, 299:F1278-F1287.
-
(2010)
Am J Physiol Renal Physiol
, vol.299
-
-
Canadillas, S.1
Ortega, R.2
Estepa, J.C.3
-
85
-
-
34547815735
-
Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression
-
Eto N., Wada T., Inagi R., et al. Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int 2007, 72:455-463.
-
(2007)
Kidney Int
, vol.72
, pp. 455-463
-
-
Eto, N.1
Wada, T.2
Inagi, R.3
-
86
-
-
34547746055
-
Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo
-
Logar C.M., Brinkkoetter P.T., Krofft R.D., Pippin J.W., Shankland S.J. Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney Int 2007, 72:489-498.
-
(2007)
Kidney Int
, vol.72
, pp. 489-498
-
-
Logar, C.M.1
Brinkkoetter, P.T.2
Krofft, R.D.3
Pippin, J.W.4
Shankland, S.J.5
-
87
-
-
3042677677
-
Rhu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline
-
Tapolyai M., Kadomatsu S., Perera-Chong M. rhu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline. BMC Nephrol 2003, 4:3.
-
(2003)
BMC Nephrol
, vol.4
, pp. 3
-
-
Tapolyai, M.1
Kadomatsu, S.2
Perera-Chong, M.3
-
88
-
-
22744457129
-
Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease
-
Dean B.B., Dylan M., Gano A., Knight K., Ofman J.J., Levine B.S. Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin 2005, 21:981-987.
-
(2005)
Curr Med Res Opin
, vol.21
, pp. 981-987
-
-
Dean, B.B.1
Dylan, M.2
Gano, A.3
Knight, K.4
Ofman, J.J.5
Levine, B.S.6
-
89
-
-
33751002326
-
Normalization of hemoglobin level in patients with chronic kidney disease and anemia
-
Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355:2071-2084.
-
(2006)
N Engl J Med
, vol.355
, pp. 2071-2084
-
-
Drueke, T.B.1
Locatelli, F.2
Clyne, N.3
-
90
-
-
33750983605
-
Correction of anemia with epoetin alfa in chronic kidney disease
-
Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085-2098.
-
(2006)
N Engl J Med
, vol.355
, pp. 2085-2098
-
-
Singh, A.K.1
Szczech, L.2
Tang, K.L.3
-
91
-
-
52949106154
-
Investigational drugs for diabetic nephropathy
-
Cortinovis M., Cattaneo D., Perico N., Remuzzi G. Investigational drugs for diabetic nephropathy. Expert Opin Investig Drugs 2008, 17:1487-1500.
-
(2008)
Expert Opin Investig Drugs
, vol.17
, pp. 1487-1500
-
-
Cortinovis, M.1
Cattaneo, D.2
Perico, N.3
Remuzzi, G.4
-
92
-
-
53549090148
-
Agents in development for the treatment of diabetic nephropathy
-
Goh S.Y., Jasik M., Cooper M.E. Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs 2008, 13:447-463.
-
(2008)
Expert Opin Emerg Drugs
, vol.13
, pp. 447-463
-
-
Goh, S.Y.1
Jasik, M.2
Cooper, M.E.3
-
94
-
-
70349277003
-
Effects of angiotensin II receptor blockers on diabetic nephropathy
-
Kalaitzidis R., Bakris G.L. Effects of angiotensin II receptor blockers on diabetic nephropathy. J Hypertens Suppl 2009, 27:S15-S21.
-
(2009)
J Hypertens Suppl
, vol.27
-
-
Kalaitzidis, R.1
Bakris, G.L.2
-
95
-
-
0032712434
-
Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes
-
Cooper M.E., Vranes D., Youssef S., et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999, 48:2229-2239.
-
(1999)
Diabetes
, vol.48
, pp. 2229-2239
-
-
Cooper, M.E.1
Vranes, D.2
Youssef, S.3
-
96
-
-
0035034655
-
Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes
-
de Vriese A.S., Tilton R.G., Elger M., Stephan C.C., Kriz W., Lameire N.H. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001, 12:993-1000.
-
(2001)
J Am Soc Nephrol
, vol.12
, pp. 993-1000
-
-
de Vriese, A.S.1
Tilton, R.G.2
Elger, M.3
Stephan, C.C.4
Kriz, W.5
Lameire, N.H.6
-
97
-
-
85047697288
-
2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice
-
Ichinose K., Maeshima Y., Yamamoto Y., et al. 2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes 2006, 55:1232-1242.
-
(2006)
Diabetes
, vol.55
, pp. 1232-1242
-
-
Ichinose, K.1
Maeshima, Y.2
Yamamoto, Y.3
-
98
-
-
33750713086
-
Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice
-
Sung S.H., Ziyadeh F.N., Wang A., Pyagay P.E., Kanwar Y.S., Chen S. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 2006, 17:3093-3104.
-
(2006)
J Am Soc Nephrol
, vol.17
, pp. 3093-3104
-
-
Sung, S.H.1
Ziyadeh, F.N.2
Wang, A.3
Pyagay, P.E.4
Kanwar, Y.S.5
Chen, S.6
-
99
-
-
48649099815
-
The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease
-
Eardley K.S., Kubal C., Zehnder D., et al. The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease. Kidney Int 2008, 74:495-504.
-
(2008)
Kidney Int
, vol.74
, pp. 495-504
-
-
Eardley, K.S.1
Kubal, C.2
Zehnder, D.3
-
100
-
-
60549110804
-
Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response
-
Yan S.F., Ramasamy R., Schmidt A.M. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med 2009, 87:235-247.
-
(2009)
J Mol Med
, vol.87
, pp. 235-247
-
-
Yan, S.F.1
Ramasamy, R.2
Schmidt, A.M.3
-
101
-
-
0033848466
-
Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease
-
Tanji N., Markowitz G.S., Fu C., et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000, 11:1656-1666.
-
(2000)
J Am Soc Nephrol
, vol.11
, pp. 1656-1666
-
-
Tanji, N.1
Markowitz, G.S.2
Fu, C.3
-
102
-
-
44049098885
-
RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis
-
Guo J., Ananthakrishnan R., Qu W., et al. RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J Am Soc Nephrol 2008, 19:961-972.
-
(2008)
J Am Soc Nephrol
, vol.19
, pp. 961-972
-
-
Guo, J.1
Ananthakrishnan, R.2
Qu, W.3
-
103
-
-
0037377697
-
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy
-
Wendt T.M., Tanji N., Guo J., et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003, 162:1123-1137.
-
(2003)
Am J Pathol
, vol.162
, pp. 1123-1137
-
-
Wendt, T.M.1
Tanji, N.2
Guo, J.3
-
104
-
-
0942290502
-
Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat
-
Davis B.J., Forbes J.M., Thomas M.C., et al. Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia 2004, 47:89-97.
-
(2004)
Diabetologia
, vol.47
, pp. 89-97
-
-
Davis, B.J.1
Forbes, J.M.2
Thomas, M.C.3
-
105
-
-
77649119983
-
Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy
-
Tan A.L., Sourris K.C., Harcourt B.E., et al. Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. Am J Physiol Renal Physiol 2010, 298:F763-F770.
-
(2010)
Am J Physiol Renal Physiol
, vol.298
-
-
Tan, A.L.1
Sourris, K.C.2
Harcourt, B.E.3
-
106
-
-
77951622247
-
Potential new therapeutic agents for diabetic kidney disease
-
Turgut F., Bolton W.K. Potential new therapeutic agents for diabetic kidney disease. Am J Kidney Dis 2010, 55:928-940.
-
(2010)
Am J Kidney Dis
, vol.55
, pp. 928-940
-
-
Turgut, F.1
Bolton, W.K.2
-
107
-
-
72449124626
-
The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice
-
Watson A.M., Li J., Schumacher C., et al. The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 2010, 53:192-203.
-
(2010)
Diabetologia
, vol.53
, pp. 192-203
-
-
Watson, A.M.1
Li, J.2
Schumacher, C.3
-
108
-
-
62149126622
-
Avosentan reduces albumin excretion in diabetics with macroalbuminuria
-
Wenzel R.R., Littke T., Kuranoff S., et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009, 20:655-664.
-
(2009)
J Am Soc Nephrol
, vol.20
, pp. 655-664
-
-
Wenzel, R.R.1
Littke, T.2
Kuranoff, S.3
-
109
-
-
77949877308
-
Avosentan for overt diabetic nephropathy
-
Mann J.F., Green D., Jamerson K., et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010, 21:527-535.
-
(2010)
J Am Soc Nephrol
, vol.21
, pp. 527-535
-
-
Mann, J.F.1
Green, D.2
Jamerson, K.3
-
111
-
-
77951199503
-
The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy
-
Jiang T., Huang Z., Lin Y., Zhang Z., Fang D., Zhang D.D. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 2010, 59:850-860.
-
(2010)
Diabetes
, vol.59
, pp. 850-860
-
-
Jiang, T.1
Huang, Z.2
Lin, Y.3
Zhang, Z.4
Fang, D.5
Zhang, D.D.6
-
112
-
-
79953242026
-
New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress
-
Sporn M.B., Liby K.T., Yore M.M., Fu L., Lopchuk J.M., Gribble G.W. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J Nat Prod 2011, 74:537-545.
-
(2011)
J Nat Prod
, vol.74
, pp. 537-545
-
-
Sporn, M.B.1
Liby, K.T.2
Yore, M.M.3
Fu, L.4
Lopchuk, J.M.5
Gribble, G.W.6
-
113
-
-
13344293711
-
Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor
-
Ishii H., Jirousek M.R., Koya D., et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996, 272:728-731.
-
(1996)
Science
, vol.272
, pp. 728-731
-
-
Ishii, H.1
Jirousek, M.R.2
Koya, D.3
-
114
-
-
0034053336
-
Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes
-
Koya D., Haneda M., Nakagawa H., et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000, 14:439-447.
-
(2000)
FASEB J
, vol.14
, pp. 439-447
-
-
Koya, D.1
Haneda, M.2
Nakagawa, H.3
-
115
-
-
28644442122
-
The effect of ruboxistaurin on nephropathy in type 2 diabetes
-
Tuttle K.R., Bakris G.L., Toto R.D., McGill J.B., Hu K., Anderson P.W. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005, 28:2686-2690.
-
(2005)
Diabetes Care
, vol.28
, pp. 2686-2690
-
-
Tuttle, K.R.1
Bakris, G.L.2
Toto, R.D.3
McGill, J.B.4
Hu, K.5
Anderson, P.W.6
-
116
-
-
34548836596
-
Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease
-
Tuttle K.R., McGill J.B., Haney D.J., Lin T.E., Anderson P.W. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin J Am Soc Nephrol 2007, 2:631-636.
-
(2007)
Clin J Am Soc Nephrol
, vol.2
, pp. 631-636
-
-
Tuttle, K.R.1
McGill, J.B.2
Haney, D.J.3
Lin, T.E.4
Anderson, P.W.5
-
117
-
-
20544477176
-
Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice
-
Lassila M., Jandeleit-Dahm K., Seah K.K., et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 2005, 16:363-373.
-
(2005)
J Am Soc Nephrol
, vol.16
, pp. 363-373
-
-
Lassila, M.1
Jandeleit-Dahm, K.2
Seah, K.K.3
-
118
-
-
77953013434
-
Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy
-
Rossini M., Naito T., Yang H., et al. Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy. Nephrol Dial Transplant 2010, 25:1803-1810.
-
(2010)
Nephrol Dial Transplant
, vol.25
, pp. 1803-1810
-
-
Rossini, M.1
Naito, T.2
Yang, H.3
-
119
-
-
77149170059
-
Protective effect of sulodexide on podocyte injury in adriamycin nephropathy rats
-
Chen S., Fang Z., Zhu Z., Deng A., Liu J., Zhang C. Protective effect of sulodexide on podocyte injury in adriamycin nephropathy rats. J Huazhong Univ Sci Technolog Med Sci 2009, 29:715-719.
-
(2009)
J Huazhong Univ Sci Technolog Med Sci
, vol.29
, pp. 715-719
-
-
Chen, S.1
Fang, Z.2
Zhu, Z.3
Deng, A.4
Liu, J.5
Zhang, C.6
-
120
-
-
77955440687
-
Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy
-
Blouza S., Dakhli S., Abid H., et al. Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy. J Nephrol 2010, 23:415-424.
-
(2010)
J Nephrol
, vol.23
, pp. 415-424
-
-
Blouza, S.1
Dakhli, S.2
Abid, H.3
-
121
-
-
78649318718
-
Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus
-
Broekhuizen L.N., Lemkes B.A., Mooij H.L., et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010, 53:2646-2655.
-
(2010)
Diabetologia
, vol.53
, pp. 2646-2655
-
-
Broekhuizen, L.N.1
Lemkes, B.A.2
Mooij, H.L.3
-
122
-
-
51749093569
-
Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials
-
Pan Y., Guo L.L., Jin H.M. Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2008, 88:660-666.
-
(2008)
Am J Clin Nutr
, vol.88
, pp. 660-666
-
-
Pan, Y.1
Guo, L.L.2
Jin, H.M.3
-
123
-
-
0035022816
-
Dietary phytoestrogens: a possible role in renal disease protection
-
Velasquez M.T., Bhathena S.J. Dietary phytoestrogens: a possible role in renal disease protection. Am J Kidney Dis 2001, 37:1056-1068.
-
(2001)
Am J Kidney Dis
, vol.37
, pp. 1056-1068
-
-
Velasquez, M.T.1
Bhathena, S.J.2
-
124
-
-
60449105133
-
The ethyl acetate extract of alfalfa sprout ameliorates disease severity of autoimmune-prone MRL-lpr/lpr mice
-
Hong Y.H., Huang C.J., Wang S.C., Lin B.F. The ethyl acetate extract of alfalfa sprout ameliorates disease severity of autoimmune-prone MRL-lpr/lpr mice. Lupus 2009, 18:206-215.
-
(2009)
Lupus
, vol.18
, pp. 206-215
-
-
Hong, Y.H.1
Huang, C.J.2
Wang, S.C.3
Lin, B.F.4
-
125
-
-
65949101874
-
Moderate exercise attenuates caspase-3 activity, oxidative stress, and inhibits progression of diabetic renal disease in db/db mice
-
Ghosh S., Khazaei M., Moien-Afshari F., et al. Moderate exercise attenuates caspase-3 activity, oxidative stress, and inhibits progression of diabetic renal disease in db/db mice. Am J Physiol Renal Physiol 2009, 296:F700-F708.
-
(2009)
Am J Physiol Renal Physiol
, vol.296
-
-
Ghosh, S.1
Khazaei, M.2
Moien-Afshari, F.3
-
126
-
-
78049292766
-
Weight loss: a neglected intervention in the management of chronic kidney disease
-
Ibrahim H.N., Weber M.L. Weight loss: a neglected intervention in the management of chronic kidney disease. Curr Opin Nephrol Hypertens 2010, 19:534-538.
-
(2010)
Curr Opin Nephrol Hypertens
, vol.19
, pp. 534-538
-
-
Ibrahim, H.N.1
Weber, M.L.2
-
127
-
-
77955756027
-
Obesity-related glomerulopathy: body mass index and proteinuria
-
Shen W.W., Chen H.M., Chen H., Xu F., Li L.S., Liu Z.H. Obesity-related glomerulopathy: body mass index and proteinuria. Clin J Am Soc Nephrol 2010, 5:1401-1409.
-
(2010)
Clin J Am Soc Nephrol
, vol.5
, pp. 1401-1409
-
-
Shen, W.W.1
Chen, H.M.2
Chen, H.3
Xu, F.4
Li, L.S.5
Liu, Z.H.6
|